Endocrinology and Metabolism

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes

Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung

Endocrinol Metab. 2019;34(4):382-389. Published online December 23, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.4.382

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

Sang Youl Rhee

Endocrinology and Metabolism. 2020;35(1):192

Link1 Link2 Link3

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes

Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung

Endocrinology and Metabolism. 2019;34(4):382

Link1 Link2 Link3

Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

Han Na Jang, Hye Seung Jung

Endocrinology and Metabolism. 2020;35(1):194

Link1 Link2 Link3

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial

Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi

Diabetes & Metabolism Journal. 2019;43:

Link1 Link2 Link3

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

Y. Onishi, Y. Ono, R. Rabøl, L. Endahl, S. Nakamura

Diabetes, Obesity and Metabolism. 2013;15(9):826-832

Link1

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

E. Franek, M. Haluzík, S. Canecki Varžić, M. Sargin, S. Macura, J. Zacho, J. S. Christiansen

Diabetic Medicine. 2015;33(4):497-505

Link1 Link2 Link3

Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study

S. Kumar, H. C. Jang, N. G. Demirağ, T. V. Skjøth, L. Endahl, B. Bode

Diabetic Medicine. 2016;34(2):180-188

Link1 Link2 Link3

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues

Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova

Diabetes mellitus. 2014;17(4):108-119

Link1 Link2

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

Ajay Kumar, Edward Franek, Jonathan Wise, Marcus Niemeyer, Henriette Mersebach, Rafael Simó

PLOS ONE. 2016;11(10):e0163350

Link1

Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study

Yoshio Nagai, Ami Nishine, Eriko Hashimoto, Taiga Nakayama, Yosuke Sasaki, Mariko Murakami, Satoshi Ishii, Hiroyuki Kato, Yasushi Tanaka

Journal of Diabetes Investigation. 2017;9(3):567-572

Link1 Link2